Clinical characteristics and outcomes of dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid patients: A retrospective study - 22/11/24
Doi : 10.1016/j.jaad.2024.09.067
Inkin Ujiie, MD, PhD a, Sho Katayama, MD a, Yosuke Mai, MD, PhD a, Shoko Mai, MD, PhD a, Norihiro Yoshimoto, MD, PhD a, Ken Muramatsu, MD, PhD a, Hiroaki Iwata, MD, PhD b, Kentaro Izumi, MD, PhD a, Hideyuki Ujiie, MD, PhD a, ⁎ 
a Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
b Department of Dermatology, Gifu University Graduate School of Medicine, Gifu, Japan
∗Correspondence to: Hideyuki Ujiie, MD, PhD, Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, N15 W7, Kita-ku, Sapporo, 060-8638, JapanDepartment of DermatologyFaculty of Medicine and Graduate School of MedicineHokkaido UniversityN15 W7Kita-kuSapporo060-8638Japan
Sous presse. Épreuves corrigées par l'auteur.
Disponible en ligne depuis le Friday 22 November 2024
Key words : anti-BP180NC16a antibody, anti-full-length BP180 antibody, bullous pemphigoid, bullous pemphigoid disease area index, clinical characteristics, dipeptidyl peptidase-4 inhibitor
| Funding sources: This work was supported in part by JSPS KAKENHI Grant number JP21H02938 (Grant-in-Aid for Scientific Research [B]) to H.U., by AMED under Grant Number JP20ek0109430 to H.U., by a grant for Research on Measures for Intractable Diseases from the Ministry of Health, Labor, and Welfare of Japan to H.U., by The Uehara Memorial Foundation, and by the Project for Junior Scientist Promotion of Hokkaido University. |
|
| Patient consent: Consent for the publication of recognizable patient photographs or other identifiable material was obtained by the authors and included at the time of article submission to the journal stating that all patients gave consent with the understanding that this information may be publicly available. |
|
| IRB approval status: Reviewed and approved by the local ethics committee and the Institutional Review Board of Hokkaido University (approval #15-025). |
© 2024
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?